SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: harkenman who wrote (66)3/14/1997 3:06:00 PM
From: KurtVedder   of 998
 
You're getting off the point now. Originally, I responded to your posts because you were saying Myotophin was a joke. Now you are talking as if it will be approved but it won't sell. I can live with that assumption. First of all, analysts have no idea how well this will sell. No one does. Provigil, which you consistently ignore, is the big one here. And I highly doubt that this drug won't sell. I agree with you that Cephalon is risky. But I like their chances. You still are not giving me reasons why this stock will go down other than analysts predicting lower earnings. The reason for the downturn (slight, I might add) is due to the mediocre sales of Rilutek. Rilutek is not Myotrophin. Believe me.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News